RT Journal Article
T1 Genetic variants associated with T cell-mediated cutaneous adverse drug reactions: A PRISMA-compliant systematic review-An EAACI position paper.
A1 Oussalah, Abderrahim
A1 Yip, Vincent
A1 Mayorga, Cristobalina
A1 Blanca, Miguel
A1 Barbaud, Annick
A1 Nakonechna, Alla
A1 Cernadas, Josefina
A1 Gotua, Maia
A1 Brockow, Knut
A1 Caubet, Jean-Christoph
A1 Bircher, Andreas
A1 Atanaskovic-Markovic, Marina
A1 Demoly, Pascal
A1 Kase-Tanno, Luciana
A1 Terreehorst, Ingrid
A1 Laguna, Jose Julio
A1 Romano, Antonino
A1 Gueant, Jean-Louis
A1 Pirmohamed, Munir
K1 T cell-mediated drug hypersensitivity reactions
K1 Cutaneous adverse drug reactions
K1 Genetic variants
K1 Human leukocyte antigen genes
K1 Systematic review
AB Drug hypersensitivity reactions (DHRs) are associated with high global morbidity and mortality. Cutaneous T cell-mediated reactions classically occur more than 6 hours after drug administration and include life-threatening conditions such as toxic epidermal necrolysis, Stevens-Johnson syndrome, and hypersensitivity syndrome. Over the last 20 years, significant advances have been made in our understanding of the pathogenesis of DHRs with the identification of human leukocyte antigens as predisposing factors. This has led to the development of pharmacogenetic screening tests, such as HLA-B*57:01 in abacavir therapy, which has successfully reduced the incidence of abacavir hypersensitivity reactions. We have completed a PRISMA-compliant systematic review to identify genetic associations that have been reported in DHRs. In total, 105 studies (5554 cases and 123 548 controls) have been included in the review reporting genetic associations with carbamazepine (n = 31), other aromatic antiepileptic drugs (n = 24), abacavir (n = 11), nevirapine (n = 14), trimethoprim-sulfamethoxazole (n = 11), dapsone (n = 4), allopurinol (n = 10), and other drugs (n = 5). The most commonly reported genetic variants associated with DHRs are located in human leukocyte antigen genes and genes involved in drug metabolism pathways. Increasing our understanding of genetic variants that contribute to DHRs will allow us to improve diagnosis, develop new treatments, and predict and prevent DHRs in the future.
PB John Wiley and Sons
YR 2020
FD 2020-05-18
LK http://hdl.handle.net/10668/14914
UL http://hdl.handle.net/10668/14914
LA en
NO Oussalah A, Yip V, Mayorga C, Blanca M, Barbaud A, Nakonechna A, et al. Genetic variants associated with T cell-mediated cutaneous adverse drug reactions: A PRISMA-compliant systematic review-An EAACI position paper. Allergy. 2020 May;75(5):1069-1098
DS RISalud
RD Apr 7, 2025